NeuDirection Limited

Company

Hong Kong biotech founded in October 2023, co-founded by Prof. Jufang He (City University of Hong Kong) and Prof. Micky Tortorella (drug development experience from global pharmaceutical companies). A spin-off from CRMH/HKISI/CAS focused on small-molecule and neuropeptide-based drugs targeting unexplored GPCRs in the brain. Developer of NEU-002 for tinnitus, alongside NEU-001 for amblyopia and NEU-003 for memory deficit syndromes. Scientific advisor and investor Prof. Tomas Hokfelt (Karolinska Institute).

Treatments

Targets

Explore connections· click any item to explore

Treatments1

NEU-002

Targets1

Cortical Tonotopic Map Reorganization

Mechanisms5

Auditory Cortex Tonotopy Lesion-Edge Overrepresentation Reorganization-Loudness Correlation Enriched Acoustic Environment Protection Hearing-Loss vs. Tinnitus Dissociation

Researchers1

Jufang He

Laboratories1

He Laboratory